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A B S T R A C T   
Amiodarone is an anti-arrhythmic drug widely used, but its administration can be associated with several adverse 
side-effects. Among these, amiodarone-induced pulmonary toxicity (APT) occurs in 4–17% of cases and, if not 
early diagnosed and treated, may evolve towards pulmonary fibrosis and respiratory failure. 
A 76 years-old-man went to the hospital for accidental trauma. The patient did not report respiratory 
symptoms but was suffering from atrial fibrillation treated with amiodarone 200 mg/day from three years 
(cumulative dose >150 gr). HRCT showed ground-glass opacities and nodules in both lungs. The patient un-
derwent fibreoptic bronchoscopy with BAL. Cytologic examination of BALF sediment put in evidence foamy 
macrophages. The electronic microscopy revealed into the alveolar macrophages “… the presence of multi-
lamellar intracytoplasmic bodies and lysosomes, loads of lipid material”. LFTs showed a restrictive syndrome and 
an impairment of DLCO. Amiodarone discontinuation and steroid administration led to the regression of 
radiological lesions and the recovery of lung function. 
Patients taking amiodarone can experience APT. They should perform a basal chest x-ray with LFTs before 
starting therapy. Monitoring could reveal early the pulmonary toxicity, and patients can respond favourably to 
the treatment.   
1. Introduction 
Amiodarone hydrochloride is a very effective drug used to treat and 
prevent a wide range of cardiac arrhythmias [1,2]. This drug and its 
metabolite desethylamiodarone have a long half-life (55–60 days) and a 
lipophilic nature that leads them to accumulate in the tissues at high 
concentrations and to interfere with the metabolism of phospholipids 
[3]. Furthermore, adverse side effects can arise or even organ toxicity 
[4–8]. The most common is related to microdeposits in corneal and 
thyroid tissue, appearing in 85–100% of patients who receive chronic 
treatment. The incidence of amiodarone pulmonary toxicity (APT) 
varies from about 4 to 17% of patients and is related to dosage, age of the 
patient, and pre-existing lung diseases. These effects reach a plateau 
with a cumulative-dose >150 gr. Underlying pathologies, general 
anaesthesia, oxygen administration, invasive or surgical procedures 
seem to promote the onset of amiodarone-induced pulmonary toxicity 
[9–12]. APT can cause a variety of clinical presentation, from alveo-
lar/interstitial pneumonitis with a subacute onset to respiratory distress 
with severe hypoxemia [6,13]. In this context, chest x-rays and 
high-resolution computed tomography (HRCT) are essential for the 
diagnosis, revealing changes in pulmonary parenchyma, as ground-glass 
opacities, or fibrosis areas, or nodules. Also, lung function tests put in 
evidence a restrictive syndrome with an impaired diffusion of the lung 
for carbon monoxide (DLCO) [3–8]. 
In this paper, we describe a patient who received a chronic home 
dose of amiodarone for more than three years (cumulative dose >150gr) 
and showed pulmonary toxicity. APT came back with drug discontinu-
ation and steroids. 
2. Case presentation 
A 76 years old man, never smoker, went to an Emergency 
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Department in July 2016 (three years ago) for an accidental fall. The 
patient performed chest x-ray that evidenced bilateral pulmonary 
opacities, but without significant respiratory symptoms. Antibiotics 
gave poor results, and he underwent HRCT. It revealed multiple 
confluent ground-glass opacities associated with regions of alveolar 
filling in both upper lobes, middle one, in the lingula, and the basal 
segment of the lower area (Fig. 1). 
From medical history emerged that the patient was taking amio-
darone 200 mg once daily from more than three years for atrial fibril-
lation. He underwent fiberoptic bronchoscopy, and bronchoalveolar 
lavage (BAL) in the middle lobe got a recovery of 50%. The cytologic 
exam on the sediment did not show atypical cells. Cell count/ml was 
equal to 200,000/mm3, with 51% of macrophages, 24% of lymphocytes, 
5% of neutrophils and 20% of eosinophils. BALF specimens did not 
reveal any bacterial growth. Electron microscopy analysis showed 
alveolar macrophages with multilamellar intracytoplasmic bodies and 
lysosomes loads of lipid material; sometimes, this material also pre-
cipitates in the form of crystals” (Fig. 2). 
(A) Alveolar macrophage with many lysosomes and lamellated in-
clusions. (B–C) Details of macrophage cytoplasm containing large 
lysosomal bodies, no uniform in size. Legend: Nu, nucleus; PM, plasma 
membrane; LB, lysosomal bodies. [TEM, uranyl acetate/lead citrate; 
Morgagni 268D Electron Microscopy - FEI Company, Hillsboro]. 
Lung function tests showed a restrictive syndrome (Table 1, A); also, 
the DLCO was impaired (61%). 
The lung lesions were attributed to APT considering the character-
istics of the pathology (history, clinical and radiological and functional 
presentation, electron microscopy results on BALF sediment). 
Since the cytotoxic drug-induced damage appeared to progress 
despite the lack of related symptoms, an empirical course of steroids 
seemed appropriate even in light of the data in the literature (8–9,13). In 
our case, the HRCT and LFTs data appeared severely compromised and 
to avoid progression to fibrosis, we adopt a treatment based on the 
discontinuation of the drug associated with steroids administration. The 
aim was to favour the reabsorption of the inflammatory lesions and 
quickly avoid his possible evolution. So, the patient stopped amiodarone 
and started prednisone intake for eight months (12,5 mg once a day) 
monitoring laboratory parameters. 
Quickly, CT scans showed complete resolution, and LFTs with the 
DLCO returned to the standard value (Fig. 3; Table 1, B). HRCT check 
confirmed results two years after steroids discontinuation. 
The patient signed informed consent for the publication of his clin-
ical details and radiological images. 
3. Discussion and conclusions 
We have described a case suffering from amiodarone-induced pul-
monary toxicity (APT) with an excellent clinical response to drug 
discontinuation and steroids administration. 
Amiodarone is a drug widely used in the treatment of cardiac ar-
rhythmias, but sometimes it can cause side effects, interesting all the 
organs [1,2,8]. Pulmonary toxicity is less frequent than thyroid and eye 
involvement but is potentially the most dangerous event for the patient 
leading to respiratory failure or even death [3–14]. Lung toxicities may 
occur both in acute and in subacute/chronic forms. Among the first 
events, we can expect bronchospasm, bronchial asthma exacerbation, 
interstitial pneumonia, ARDS, diffuse alveolar haemorrhage; among the 
second events, we can expect lipoid pneumonia, chronic eosinophilic 
pneumonia, nodules or pulmonary masses. Also, amiodarone toxicity 
may induce pleural effusions or thickening [6,8]. 
The clinical presentation can range from the absence of respiratory 
symptoms to acute onset or chronic evolution. Radiological manifesta-
tions of pulmonary toxicity, without a strong clinical suspicion, are 
frequently not recognised. Risk factors for pulmonary toxicity include a 
high cumulative dose, duration of therapy exceeding two months (but 
sometimes even after a few days), existing lung diseases, increased pa-
tient age, surgery and pulmonary angiography [8–12]. 
Lung function tests typically show a restrictive syndrome. A reduc-
tion in DLCO more than 15% is a reliable indicator for amiodarone- 
induced pulmonary toxicity, with high sensitivity and specificity [4,5, 
8]. Lung biopsy, alveolar cytogram, foamy macrophages in BAL can help 
in the formulation of the diagnosis, but this is an exclusion diagnosis. 
Today, no tests are available for establishing the onset of APT and the 
diagnosis. To make a clinical diagnosis of APT requires the exclusion of 
other diagnostic possibilities (especially congestive heart failure) 
together with a reasonable constellation of symptoms or findings. 
Pulmonary imaging is essential. The high-resolution CT scan reveals 
ground-glass opacities, localised or diffuse parenchymal infiltrates mono 
or bilateral, parenchymal nodules, pneumonia, pleural thickening and 
effusions. 
Once made diagnosis of APT, the clinicians have a limited number of 
therapeutic options. 
Firstly, it is necessary to stop drug intake and replace it with another 
antiarrhythmic agent or arrange other possibilities, in agreement with 
the cardiologist. If the toxicity manifestations are limited, usually the 
suspension alone of the drug leads to clinical and radiological 
improvement. But if the signs of toxicity are of a relevant entity or if 
chest x-ray changes do not regress, systemic corticosteroids are recom-
mended for APT although controlled trials are lacking. Prednisolone is 
usually used at a dose of 0.5/1mg per Kg of weight and for a long time, 
up to a year. The goal is the regression of complication and complete 
recovery. In severe APT, the therapy can range from steroids at a high 
dose to mechanical ventilation. To underline that after the initial attack 
phase, corticosteroids should be continued for a long time, checking the 
evolution of clinical data, blood gases, LFTs and chest x-ray [4,5,8–13]. 
Pulmonary toxicity may initially progress despite drug stopping or even 
recur upon steroid withdrawal, probably for the long half-life of amio-
darone. The clinical answer depends on the individual sensitivity to 
treatment and the prolonged persistence of the drug at high concen-
tration in the lung tissue, even over 90 days [14]. 
In this report, we focused our attention to a patient suffering from 
APT. He had taken amiodarone 200 mg once a day for more years for 
atrial fibrillation (cumulative dose > 150 gr). At admission in hospital 
for an accidental trauma, he did not have respiratory symptoms. But 
HRCT showed widespread ground-glass opacities and pulmonary nod-
ules, while LFTs revealed a restrictive syndrome and a reduced DLCO, 
more than 15%. Cytology and electronic microscopy performed on BALF 
revealed foamy macrophages, lipid-laden. The drug discontinuation and 
steroids administration for a long time, even if at low doses to avoid the 
side effects of cortisone, shortly led to the disappearance of symptoms 
Fig. 1. Baseline CT scans showing bilateral ground-glass opacities and pul-
monary consolidation. 
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and the improvement of radiological and functional findings. Controls 
after two years did not reveal any relapse. 
In conclusion, diagnosis of APT is not easy because of multiform 
clinical aspects of this complication. Indeed, we must consider it among 
the differential diagnoses in patients who use of amiodarone, and with 
progressive or acute respiratory symptoms or who are presenting 
radiological interstitial lesions, also in the absence of symptoms. There is 
no diagnostic test pathognomonic for APT, but this is a diagnosis of 
exclusion made on clinical, laboratory and radiographic findings. All 
patients taking amiodarone should perform a chest x-ray, and LFTs 
before starting therapy, and then patients should be followed carefully 
and monitored appropriately. With a prompt diagnosis, patients can 
respond favourably to drug discontinuation and steroids administration. 
Of course, this statement requires controlled studies based on a large 
number of cases. 
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